search
Back to results

HEAL Study: Healing Results, Efficacy and Acceptability of a New Contact Layer (HEAL)

Primary Purpose

Wound

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
URGO AWC_019 dressing (AWC=Advanced Wound Care)
Sponsored by
Laboratoires URGO
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Wound

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

A. Related to every wounds types:

  • Patient over 18 years old who has provided his/her written informed consent
  • Patient affiliated to the French Social insurance
  • Patient who can be monitored by the same investigation team throughout the whole duration of the study,
  • Acute wound (postoperative non-cavitary and non-sutured wound, superficial, middle or deep second degree burn, dermabrasion) or chronic wound (venous or mixed leg ulcer, pressure ulcer) or epidermolysis bullosa skin lesion
  • Use of a contact layer as a primary dressing justified by the wound

B. Related to leg ulcer:

  • Venous leg ulcer or mixed leg ulcer, i.e. with an Ankle Brachial Pressure Index (ABPI) not less than 0.7 and not more than 1.3, (0.7≤ABPI≤ 1.3)
  • Patient who agrees to wear an effective venous compression system every day, associated with the trial dressing

C. Related to pressure ulcer:

  • Stage 2, 3 according to the EPUAP (European Pressure Ulcer Advisory Panel) classification system
  • Wound on the pelvis (trochanter, ischio or sacrum) or on the heel

Exclusion Criteria:

  • Patient under authorship or guardianship
  • Woman of child-bearing potential who has no effective contraception method
  • Pregnant or breastfeeding woman
  • Patient taking part in another clinical trial
  • Patient with a known allergy to carboxymethylcellulose (hydrocolloid),
  • Patient with a severe illness that might lead to the premature discontinuation of the trial before the 4 weeks of treatment
  • Wound requiring surgical treatment or for which surgery is scheduled during the 4 weeks after inclusion
  • Patient with an evolving neoplasia condition, treated by radiotherapy, chemotherapy or hormone therapy
  • Malignant wound
  • Patient with a systemic infection not controlled by suitable antibiotic treatment,
  • Wound which is clinically infected

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    URGO AWC_019 dressing (AWC=Advanced Wound Care)

    Arm Description

    URGO AWC_019 dressing (AWC=Advanced Wound Care)

    Outcomes

    Primary Outcome Measures

    Relative evolution of the wound surface (in %) at week 4
    Relative evolution of the wound surface (in %) at week 4

    Secondary Outcome Measures

    - Pain on wound URGO AWC_019 dressing removal (measured thanks to Analogical Visual Scale: no pain = 0 mm and unbearable pain = 100 mm)
    - Pain on wound URGO AWC_019 dressing removal (measured thanks to Analogical Visual Scale: no pain = 0 mm and unbearable pain = 100 mm)
    - Wound dressing safety (occurrence of adverse events)
    - Wound dressing safety (occurrence of adverse events)
    - Percentage of healed wounds (healing rate) after 4 weeks of treatment
    - Percentage of healed wounds (healing rate) after 4 weeks of treatment
    - Wound healing time (in days)
    - Wound healing time (in days)

    Full Information

    First Posted
    August 3, 2018
    Last Updated
    August 21, 2018
    Sponsor
    Laboratoires URGO
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03640871
    Brief Title
    HEAL Study: Healing Results, Efficacy and Acceptability of a New Contact Layer
    Acronym
    HEAL
    Official Title
    Assessment of Efficacy, Tolerance and Acceptability for the Wound Dressing URGO AWC_019 in the Local Treatment of Acute Wounds, Chronic Wounds and Epidermolysis Bullosa Skin Lesions
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2018
    Overall Recruitment Status
    Unknown status
    Study Start Date
    October 2018 (Anticipated)
    Primary Completion Date
    November 2019 (Anticipated)
    Study Completion Date
    November 2019 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Laboratoires URGO

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Assessment of efficacy, tolerance and acceptability for the wound dressing URGO AWC_019 in the treatment of acute wounds, chronic wounds and epidermolysis bullosa skin lesions
    Detailed Description
    Non-comparative clinical study, conducted in France, to evaluate efficacy, tolerance and acceptability for the wound dressing URGO AWC_019 in the treatment of acute wounds, chronic wounds and epidermolysis bullosa skin lesions

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Wound

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    80 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    URGO AWC_019 dressing (AWC=Advanced Wound Care)
    Arm Type
    Experimental
    Arm Description
    URGO AWC_019 dressing (AWC=Advanced Wound Care)
    Intervention Type
    Device
    Intervention Name(s)
    URGO AWC_019 dressing (AWC=Advanced Wound Care)
    Intervention Description
    URGO AWC_019 dressing 10x10 cm (AWC=Advanced Wound Care)
    Primary Outcome Measure Information:
    Title
    Relative evolution of the wound surface (in %) at week 4
    Description
    Relative evolution of the wound surface (in %) at week 4
    Time Frame
    4 weeks
    Secondary Outcome Measure Information:
    Title
    - Pain on wound URGO AWC_019 dressing removal (measured thanks to Analogical Visual Scale: no pain = 0 mm and unbearable pain = 100 mm)
    Description
    - Pain on wound URGO AWC_019 dressing removal (measured thanks to Analogical Visual Scale: no pain = 0 mm and unbearable pain = 100 mm)
    Time Frame
    4 weeks
    Title
    - Wound dressing safety (occurrence of adverse events)
    Description
    - Wound dressing safety (occurrence of adverse events)
    Time Frame
    4 weeks
    Title
    - Percentage of healed wounds (healing rate) after 4 weeks of treatment
    Description
    - Percentage of healed wounds (healing rate) after 4 weeks of treatment
    Time Frame
    4 weeks
    Title
    - Wound healing time (in days)
    Description
    - Wound healing time (in days)
    Time Frame
    4 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    100 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: A. Related to every wounds types: Patient over 18 years old who has provided his/her written informed consent Patient affiliated to the French Social insurance Patient who can be monitored by the same investigation team throughout the whole duration of the study, Acute wound (postoperative non-cavitary and non-sutured wound, superficial, middle or deep second degree burn, dermabrasion) or chronic wound (venous or mixed leg ulcer, pressure ulcer) or epidermolysis bullosa skin lesion Use of a contact layer as a primary dressing justified by the wound B. Related to leg ulcer: Venous leg ulcer or mixed leg ulcer, i.e. with an Ankle Brachial Pressure Index (ABPI) not less than 0.7 and not more than 1.3, (0.7≤ABPI≤ 1.3) Patient who agrees to wear an effective venous compression system every day, associated with the trial dressing C. Related to pressure ulcer: Stage 2, 3 according to the EPUAP (European Pressure Ulcer Advisory Panel) classification system Wound on the pelvis (trochanter, ischio or sacrum) or on the heel Exclusion Criteria: Patient under authorship or guardianship Woman of child-bearing potential who has no effective contraception method Pregnant or breastfeeding woman Patient taking part in another clinical trial Patient with a known allergy to carboxymethylcellulose (hydrocolloid), Patient with a severe illness that might lead to the premature discontinuation of the trial before the 4 weeks of treatment Wound requiring surgical treatment or for which surgery is scheduled during the 4 weeks after inclusion Patient with an evolving neoplasia condition, treated by radiotherapy, chemotherapy or hormone therapy Malignant wound Patient with a systemic infection not controlled by suitable antibiotic treatment, Wound which is clinically infected
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Clémence Ms Tumba, PharmD
    Phone
    ++33380447409
    Email
    c.tumba@fr.urgo.com

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    HEAL Study: Healing Results, Efficacy and Acceptability of a New Contact Layer

    We'll reach out to this number within 24 hrs